BEVERLY HILLS, Calif.,today announced that - Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to provide this update detailing recent comments made by Dr. Hootan Melamed, whose family's Beverly Hills, CA based Rox San Pharmacy is the original compounding Pharmacy for Tropine 3, a Novel indication of Homatropine in oral suspension. Dr. Melamed filed the Patent for the drug's new indication for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.
"Over the last six years, the Rox San Pharmacy team has been compounding Tropine 3 for southern California doctors that prescribe the drug to their patients for the treatment of hot flashes. Based on our interactions with the doctors and patients, it is our belief that Tropine 3 users have had a generally very positive response to the drug with no pronounced negative side-effects," stated Dr. Hootan Melamed.
"It is obvious that women across America and around the world could benefit from open access to this new drug, so we are very excited to see Eaton Scientific making progress in executing its plan to seek FDA Approval and fully commercialize Tropine 3. We would like to see our experience with the positive effects of the oral suspension version of Homatropine that Eaton has named Tropine 3 in a FDA Clinical Trial and move towards having Tropine 3 available for all women suffering from the effects of hot flashes."
Rox San Pharmacy has over 40 years of experience with a highly-qualified and educated team of pharmacists, technicians, and chemists to custom prepare high-quality compounded and manufactured medications using several unique delivery systems including, but not limited to, lozenges, nasal spray, cream, lotion, or transdermal gel. Rox San Pharmacy services are utilized by a variety of health care participants, including new drug developers, dermatologists, plastic surgeons, orthopedic surgeons, and pain care specialists.
PR Newswire